in at $1.06, page-42

do not be so naive, ranbaxy must be selling at a lost to capature market share and afterwards prices will go up.
the actual of manufacturing is small comparatively to the cost of operating in high cost countries like australia.
its the overheads, cost of staff and distribution costs that make up the bulk of the costs and these are determined locally.
the real question is the business model and management